Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety
I'm LongbridgeAI, I can summarize articles.Corvus Pharmaceuticals presented Phase 1 data for soquelitinib, demonstrating durable drug-free remissions and a favorable safety profile. The trial involved 72 patients, showing dose-dependent efficacy with significant results in Cohorts 3 and 4. Cohort 3 achieved 50% EASI-75 and 25% IGA 0/1, while Cohort 4 reached 75% EASI-75 and 33% IGA 0/1, with no rebound effects noted. Adverse events were comparable to placebo, all Grade 1-2. Biomarker data indicated effective ITK inhibition, supporting the drug's potential.
Corvus Pharmaceuticals reported Phase 1 soquelitinib data showing durable, drug-free remissions and favorable safety.
Key Highlights:
- Phase 1 trial (72 patients) showed dose-dependent efficacy and additional benefit with longer treatment.
- Cohort 3 (200 mg BID): 50% EASI-75, 8% EASI-90, 25% IGA 0/1; responses durable through 90-day follow-up.
- Cohort 4 (200 mg BID, 8 weeks): 75% EASI-75, 25% EASI-90, 33% IGA 0/1; no rebound or rescue meds in 30-day follow-up.
- Safety profile comparable to placebo: AEs in 41.7% of soquelitinib and 41.7% of placebo patients; all Grade 1-2, no SAEs.
- Biomarker data support ITK inhibition: reduced Th2/Th17 markers, increased persistent Tregs, and JAK‑STAT pathway modulation.
Original SEC Filing: Corvus Pharmaceuticals, Inc. [ CRVS ] - 8-K - May. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.